These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34851749)

  • 1. Comparative Minimal Inhibitory and Mutant Prevention Concentration of Eight Antimicrobial Agents Against
    Yang F; Chen P; Wang H; Xing X; Wang S; Ishaq HM; Liao W
    Microb Drug Resist; 2022 Feb; 28(2):229-235. PubMed ID: 34851749
    [No Abstract]   [Full Text] [Related]  

  • 2. Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin.
    Tang HJ; Lai CC; Chen CC; Zhang CC; Weng TC; Chiu YH; Toh HS; Chiang SR; Yu WL; Ko WC; Chuang YC
    J Microbiol Immunol Infect; 2019 Apr; 52(2):273-281. PubMed ID: 27133391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.
    Wang F; Zhou Q; Yang X; Bai Y; Cui J
    PLoS One; 2021; 16(10):e0258426. PubMed ID: 34648556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of the Novel Aminoglycoside Acetyltransferase Variant
    Sato T; Wada T; Nishijima S; Fukushima Y; Nakajima C; Suzuki Y; Takahashi S; Yokota SI
    mBio; 2020 Dec; 11(6):. PubMed ID: 33443109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tigecycline-Amikacin Combination Effectively Suppresses the Selection of Resistance in Clinical Isolates of KPC-Producing Klebsiella pneumoniae.
    Ni W; Wei C; Zhou C; Zhao J; Liang B; Cui J; Wang R; Liu Y
    Front Microbiol; 2016; 7():1304. PubMed ID: 27594855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Yim H; Woo H; Song W; Park MJ; Kim HS; Lee KM; Hur J; Park MS
    Ann Clin Lab Sci; 2011; 41(1):39-43. PubMed ID: 21325253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antibiotic combinations for colistin-resistant Klebsiella pneumoniae.
    Kádár B; Kocsis B; Tóth Á; Damjanova I; Szász M; Kristóf K; Nagy K; Szabó D
    Acta Microbiol Immunol Hung; 2013 Jun; 60(2):201-9. PubMed ID: 23827751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the in vitro activity of azithromycin niosomes alone and in combination with levofloxacin on extensively drug-resistant Klebsiella pneumoniae clinical isolates.
    Owais HM; Baddour MM; El-Metwally HAE; Barakat HS; Ammar NS; Meheissen MA
    Braz J Microbiol; 2021 Jun; 52(2):597-606. PubMed ID: 33483896
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Goel A; Gupta V; Singhal L; Palta S; Chander J
    Indian J Med Res; 2021 Mar; 154(3):520-526. PubMed ID: 35345078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant prevention concentration and mutant selection window for 10 antimicrobial agents against Rhodococcus equi.
    Berghaus LJ; Giguère S; Guldbech K
    Vet Microbiol; 2013 Oct; 166(3-4):670-5. PubMed ID: 23915992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
    Evren E; Azap OK; Çolakoğlu Ş; Arslan H
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):335-8. PubMed ID: 23726147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
    Docobo-Pérez F; Nordmann P; Domínguez-Herrera J; López-Rojas R; Smani Y; Poirel L; Pachón J
    Int J Antimicrob Agents; 2012 Mar; 39(3):251-4. PubMed ID: 22154856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?
    Cojutti P; Sartor A; Bassetti M; Scarparo C; Pea F
    J Glob Antimicrob Resist; 2018 Sep; 14():238-241. PubMed ID: 29775786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro activity of tigecycline against multiple resistant Acinetobacter baumannii and carbapenem resistant Klebsiella pneumoniae isolates].
    Arikan Akan O; Uysal S
    Mikrobiyol Bul; 2008 Apr; 42(2):209-15. PubMed ID: 18697418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region.
    Menekşe Ş; Çağ Y; Işık ME; Şahin S; Hacıseyitoğlu D; Can F; Ergonul O
    Int J Infect Dis; 2019 Sep; 86():208-211. PubMed ID: 31402295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of colistin-resistant Klebsiella pneumoniae in Poland.
    Sękowska A; Chudy M; Gospodarek-Komkowska E
    Acta Microbiol Immunol Hung; 2019 Dec; 67(1):18-22. PubMed ID: 31813256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae.
    Tascini C; Tagliaferri E; Giani T; Leonildi A; Flammini S; Casini B; Lewis R; Ferranti S; Rossolini GM; Menichetti F
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3990-3. PubMed ID: 23752510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial polymers as therapeutics for treatment of multidrug-resistant Klebsiella pneumoniae lung infection.
    Lou W; Venkataraman S; Zhong G; Ding B; Tan JPK; Xu L; Fan W; Yang YY
    Acta Biomater; 2018 Sep; 78():78-88. PubMed ID: 30031912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains.
    Carcas AJ; Sevillano D; González N; Alou L; Gómez-Gil R; Muñoz M; Llanos L; Sanchez-Villanueva RJ; Gonzalez-Parra E; Giménez MJ; Aguilar L
    J Glob Antimicrob Resist; 2019 Dec; 19():241-251. PubMed ID: 31176754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.